2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Leukemia, Myeloid, Acute
3
Leukemia
3
Vomiting
2
Stomach Neoplasms
2
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Motor Activity
2
Ventilator-Induced Lung Injury
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Substance-Related Disorders
1
Solid Tumors
1
Recurrence
1
Postoperative Complications
1
Pituitary Neoplasms
1
Pancreatic Neoplasms
1
Opioid-Related Disorders
1
Opioid-Induced Constipation
1
Neurofibromatosis 1
1
Neoplasms
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Follicular
1
Lymphoma
1
Lung Neoplasms
1
Low Anterior Resection Syndrome
1
Kidney Neoplasms
1
Hematologic Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
AZD 6244
19
trametinib
5
Lovastatin
5
Deoxycholic Acid
4
mirdametinib
3
Lasers, Solid-State
3
pirfenidone
2
fludarabine
2
binimetinib
2
Vincristine
2
Vinblastine
2
Transcranial Direct Current Stimulation
2
Specimen Handling
2
Sirolimus
2
Polidocanol
2
Magnetic Resonance Spectroscopy
2
Magnetic Resonance Imaging
2
Lasers
2
Lamotrigine
2
Inhalation
2
Everolimus
2
Carboplatin
2
Blood Specimen Collection
2
Biopsy
2
Acetylcysteine
2
tipifarnib
1
thymoglobulin
1
talimogene laherparepvec
1
pomalidomide
1
peginterferon alfa-2b
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neurofibromatosis 1
×
Dosage Forms
×
Clear all
NCT05309668
2025-12-18
SPRINKLE
AstraZeneca
Phase 1/2
Active not recruiting
36 enrolled
37 charts